RonanRX · Lloyd review · synthetic data
Drawn from the original 2 × 0.75 in Tirzepatide label template: same black medication rail, total chips, patient header, type sizes, safety margins, field placement, and QR. NAD+ and Glutathione place the drug name above the total amount, with the NAD+ name enlarged as requested. This revision removes the license number and the concentration rule on single-ingredient labels.
8ead5318d (October 9, 2026); live production differences are unverified because Google Cloud needs Cathryn to sign in. Lloyd’s 28-day-or-BUD wording, as relayed by Cathryn, is now shown on every vial proof. See the source and exception note. PR #2284 now carries the discard text for all 49 vials and maps their 2, 3, 5, 6, and 10 mL fills to one small label stock; it remains pending review and release. Storage text still missing is marked as a placeholder. The proof QR opens the Cloudflare destination preview; the production payload still expects ronanrx.com/ORDER-RECEIVED, which returns 404 until PR #2282 is released. Physical print, vial fit, and scanning remain unverified.2ml vial · 202105898
2 mg/mL · 4 mg total
2ml vial · 202105897
4 mg/mL · 8 mg total
2ml vial · 202105899
8 mg/mL · 16 mg total
2ml vial · 202553870
12 mg/mL · 24 mg total
2ml vial · 202553870
16 mg/mL · 32 mg total
2ml vial · 202105900
24 mg/mL · 48 mg total
2ml vial · 202105871
30 mg/mL · 60 mg total
2ml vial · 202105919
0.5 / 1 mg/mL · 1 / 2 mg total
2ml vial · 202105918
1 / 1 mg/mL · 2 / 2 mg total
2ml vial · 202105916
2 / 2 mg/mL · 4 / 4 mg total
2ml vial · 202105917
3.4 / 2 mg/mL · 6.8 / 4 mg total
2ml vial · 202105925
4 / 2 mg/mL · 8 / 4 mg total
2ml vial · 202066057
5 / 2 mg/mL · 10 / 4 mg total
5ml vial · 202349556
5 / 1 mg/mL · 25 / 5 mg total
2ml vial · 201539236
0.5 / 1 mg/mL · 1 / 2 mg total
2ml vial · 201548228
1 / 1 mg/mL · 2 / 2 mg total
2ml vial · 201548234
2 / 2 mg/mL · 4 / 4 mg total
2ml vial · 201548233
3.4 / 2 mg/mL · 6.8 / 4 mg total
2ml vial · 201548308
4 / 2 mg/mL · 8 / 4 mg total
2ml vial · 201539246
5 / 2 mg/mL · 10 / 4 mg total
3ml vial · 201548230
5 / 1 mg/mL · 15 / 3 mg total
5ml vial · 201548231
5 / 1 mg/mL · 25 / 5 mg total
2ml vial · 201562405
5 / 2 mg/mL · 10 / 4 mg total
2ml vial · 201562407
10 / 2 mg/mL · 20 / 4 mg total
2ml vial · 201562425
15 / 2 mg/mL · 30 / 4 mg total
2ml vial · 201562406
20 / 2 mg/mL · 40 / 4 mg total
2ml vial · 201562403
25 / 2 mg/mL · 50 / 4 mg total
2ml vial · 201602127
30 / 2 mg/mL · 60 / 4 mg total
5ml vial · 202349555
30 / 2 mg/mL · 150 / 10 mg total
2ml vial · 201539190
5 / 2 mg/mL · 10 / 4 mg total
2ml vial · 201539191
10 / 2 mg/mL · 20 / 4 mg total
2ml vial · 201539230
15 / 2 mg/mL · 30 / 4 mg total
2ml vial · 201539235
20 / 2 mg/mL · 40 / 4 mg total
2ml vial · 201539245
25 / 2 mg/mL · 50 / 4 mg total
2ml vial · 201548227
30 / 2 mg/mL · 60 / 4 mg total
5ml vial · 202349554
30 / 2 mg/mL · 150 / 10 mg total
5ml vial · 201337901
3 mg/mL · 15 mg total
6ml vial · 202085408
1.5 / 2.5 mg/mL · 9 / 15 mg total
5ml vial · 202348093
10 mg/mL · 50 mg total
3ml vial · 202553091
9 / 1.66 / 3.33 mg/mL · 27 / 4.98 / 9.99 mg total
10ml vial · 202663939
200 mg/mL · 2000 mg total
5ml vial · 202554521
2 mg/mL · 10 mg total
5ml vial · 202118679
100 mg/mL · 500 mg total
10ml vial · 201562382
100 mg/mL · 1000 mg total
5ml vial · 202477241
10 mg/mL · 50 mg total
5ml vial · 202554540
1 mg/mL · 5 mg total
3ml vial · 202553286
3.3333 mg/mL · 10 mg total
5ml vial · 202554216
2 mg/mL · 10 mg total
3ml vial · 202553090
1.66 / 3.33 mg/mL · 4.98 / 9.99 mg total
Every vial proof shows “DISCARD 28 DAYS AFTER FIRST PUNCTURE OR BUD, WHICHEVER IS EARLIER”. The USP <797> FAQ (questions 193–194) says a multiple-dose compounded sterile preparation cannot be used beyond its assigned BUD or 28 days after first puncture, whichever is sooner. FDA guidance gives the same 28-day limit after first use for compounded GLP-1 vials containing multiple doses. A BUD of 60, 90, 120, or 180 days is not an after-puncture instruction.
Use the exact line above across this proof set. It fits the small-label template.
If Lloyd identifies a single-dose vial or a formulation with a shorter in-use time, use its specific instruction and make a separate proof.
The 40 previously blank catalog rows were updated in PR #2284, which is not yet merged. Inactive Retatrutide listings also need regulatory review before any patient label. This page does not authorize production printing.
Enclomiphene is dispensed in count-based packs. A vial wrap would be the wrong package label. These 9 listings need a separate package proof:
These proofs use the editable Tirzepatide reference template as their geometry and style source. Its original QR encoded the homepage; the review proofs substitute the Cloudflare preview destination without moving the QR. The checkboxes save only in this browser; they do not send feedback or approve a label. Send Cathryn the item number, correction, and any print or scan observation.